ACE: A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA CONTROL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在世界许多地区，哮喘的患病率有所增加。有证据表明，生活在美国市中心的儿童，生活在经济条件下，构成了哮喘的独特和特殊的高危人群，其特点是发病率和死亡率增加(Akinbami等人，2002年；Cloutier等人，2002年)。 内城哮喘联合会(ICAC)的目标是(1)确定可能促进控制和预防哮喘的基于免疫的疗法的形式，(2)设计评估低收入内城青少年哮喘治疗中基于免疫的疗法的方案，以及(3)通过进行与治疗方案平行的机制调查，确定基于免疫的疗法的机制以及与低收入市中心青少年哮喘发病相关的潜在的独特机制。 生物标记物在哮喘的临床治疗中的可用性为将这一测量方法应用于特定的患者亚群提供了机会，这些患者仍然无法通过传统的哮喘治疗方法进行治疗。城市、市中心患有哮喘的青少年是一个特别易受影响的群体，他们的发病率很高。作为NAEPP指南的补充，以呼出的一氧化氮形式的生物标记物测量的潜在应用为管理和控制哮喘提供了机会。因此，廉政公署进行了一项随机、前瞻性、双盲平行分组试验，对象为12至20岁患有哮喘的内城青少年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of asthma has increased in many parts of the world. Evidence exists that children living in the inner cities of the United States, and living under economic disadvantages, constitute a unique and special at-risk population for asthma, which is characterized by increased morbidity and morality (Akinbami et al, 2002; Cloutier et al, 2002). The objectives of the National Institutes of Allergy and Infectious Diseases Inner City Asthma Consortium (ICAC) are (1) to identify forms of immune-based therapy that are likely to promote control and prevention of asthma, (2) to design protocols that will evaluate immune-based therapies in the treatment of asthma in low-income inner-city adolescents, and (3) to determine both the mechanisms of immune-based therapies and the potential unique mechanisms associated with the pathogenesis of asthma in low-income inner-city adolescents by the conduct of parallel mechanistic investigations with the therapeutic protocols. The availability of biomarkers in the clinical management of asthma presents presents an opportunity to apply this measurement to a specific subpopulation of patients who remain refractory to the conventional approach to asthma management. The population of urban, inner-city adolescents with asthma is a particularly susceptible group who are subject to a severe degree of morbidity. The potential application of biomarker measurement in the form of exhaled nitric oxide presents an opportunity to manage and control asthma as an adjunct to NAEPP guidelines. The ICAC therefore has conducted a randomized, prospective, double-blind parallel group trial involving inner city adolescents, ages 12-20 years, with persistent asthma.